Identification of novel ICD-related molecular subtypes holds promise for guiding personalized therapies, assessing prognosis, and predicting immunotherapy efficacy in LUAD. IFNG emerges as a potential prognostic biomarker and therapeutic target, influencing both the tumor microenvironment and angiogenesis.

We included ESCC patients who had received neoadjuvant therapy from three major academic institutions and provided the largest dataset of recurrence pattern data for ypT0N+ patients. Survival, recurrence pattern and timing, and potential prognostic factors were compared. Significant survival differences existed among patients with various pathological regression types who received NCRT or NRT and surgery for ESCC. The ypT0N+ group had a poorer survival rate. Besides, the distant metastasis rate in ypT0N+ was higher than that in the ypT0N0 group and similar to that in the ypT+N+ group. For these lymph node-positive patients, adjuvant chemotherapy does not appear to improve their prognosis.

The combination of HER2-low status and age plays a key role in prognostic stratification in TNBC. Patients aged ≥ 65 with HER2-0 had considerably poorer prognoses compared to other subgroups.

NRTK+ and RET+ CRC possess significantly higher TMB than other RTK+ CRC or NTRK+/RET+ non-CRC solid tumors. TMB testing should be routinely done in MSI-H CRC and where TMB  > 35 mut/MB samples should be screened for NTRK and RET fusions as an enrichment strategy to provide an additional treatment option for NTRK+ and RET+ CRC patients.

Treatment with selinexor in combination with nivolumab or nivolumab plus ipilimumab is well-tolerated. In patients with advanced renal cell carcinoma, the combination showed modest clinical activity compared to historic immunotherapy alone.

The findings of our international retrospective analysis, designated the ARON-2 study, substantiate the pivotal role of the antibody–drug conjugate enfortumab vedotin (EV) in the therapeutic strategy for previously treated advanced urothelial carcinoma (aUC). EV has been demonstrated to be more efficacious than chemotherapy in terms of overall survival (OS), progression-free survival (PFS) and overall response rate (ORR) in patients with aUC who received prior platinum-based therapy and immunotherapy, regardless of their clinical and disease characteristics.

The relationship between HPV-16 and OSCC may not be as prominent as in oropharyngeal cancer, at least within our cohort. The method developed in this study is not only applicable to oral cancer. This method's utility and versatility position it as a valuable resource for elucidating virus–cancer associations in the future.

In this statistically powered and matched-cohort real-world analysis, there was no statistically significant difference in real-world overall survival between matched patients with FGFR-altered or FGFR-negative advanced solid tumors, with a median overall survival of ~1 year in both groups. These results highlight the poor prognosis of patients with advanced solid tumors harboring FGFR alterations and the need for novel, targeted therapies.

In this phase 1, dose escalating study, venadaparib (IDX-1197) had acceptable safety profile with wide therapeutic window with no DLT observed. Clinical pharmacology assessment demonstrated favorable pharmacokinetic characteristics for once daily dosing and pharmacodynamic PAR inhibition from lower doses aligned with signal of efficacy in heavily treated patients with BRCA mutations. These warrants further investigation as monotherapy and in combination.

This study aimed to investigate the efficacy of radical resection and postoperative adjuvant chemotherapy on the survival benefit in patients with pancreatic ductal adenocarcinoma, stratified by age, frailty, and other factors in actual clinical practice. High modified frailty index was an independent prognostic factor, in addition to lymph node metastasis and CA19-9 levels, among those aged > 75 years. Frailty may be strongly related to the prognosis of elderly patients with pancreatic ductal carcinoma after radical resection.

Heart rate variability was associated with anxiety and depressive symptoms among AYAs receiving hematopoietic cell transplantation. Digital biomarkers of psychosocial symptoms may augment behavioral intervention design and implementation.

Sleep–wake disturbances are common among primary brain tumor patients. Social factors like financial toxicity and other medications, including psychotropic medications, may impact sleep more strongly when patients are more distal from diagnosis than their previous treatment course.

Triple negative breast cancer with sustained high STING expression following NAC demonstrated a poorer disease-free survival and will be a target for new treatment strategies.

Due to a disseminated metastatic pattern and no established tumor markers, early detection and monitoring of recurrences of myxoid liposarcomas are challenging. Liquid biopsy with the detection of circulating tumor DNA (ctDNA) can support diagnostics. Especially low concentrations of ctDNA can make the detection of small tumors difficult. This approach significantly improves the sensitivity and specificity of MLS liquid biopsy using unique molecular identifiers and a sophisticated bioinformatic analysis.